Member Info for TR64

In January 2020, TUI had a market cap of £7 billion with just over 500 million shares in Issue, it paid a dividend of 54 cents a share.
It as had 3 billion Euros of State loans from German banks already, before this last loan and RI. The debt of 3 billion as to be paid back as well as new debts , plus old debts,
the company is sound now, but need 27 million customers per year from now and no dividend payments for at least 3 Years.

Hopefully, it will turn round, but pinning hopes on a vaccine alone is not enough, its big profits will come from cruises once tey are back up and running.

Looking forward to stability.,once we get into March

MrLong . I have my original l holding that is long held and averaged down , having held for 5 years.

Have a read of the new release of F P Joussen
https://www.lse.co.uk/rns/TUI/tui-ag-notification-and-public-disclosure-of-transactions-by-persons-discharging-managerial-responsibilities-and-persons-closely-associated-with-them-i6xxa3tzvmqkdgr.html

GLA

avocet/

Can you read the publication on Goldman from the DAX.
thew transaction date was 11 January if you bother to read it, good idea to read it

I would say they brought the RI issue in market, what they do from here is anyones guess

Be prepared for a reversal, I sincerely hope its not more than 20%

As to the comment 50 % gain and 100%, I wont bother addressing such crap, as reasoned views are not acceptable to the Ignorant

GSK Consumer Health Care bring in big revenues, the time lay out is below

GlaxoSmithKline plc (LSE/NYSE: GSK) has reached agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture, with combined sales of approximately £9.8 billion ($12.7 billion)[1]. GSK will have a majority controlling equity interest of 68% and Pfizer will have an equity interest of 32% in the Joint Venture.

The proposed all-equity transaction represents a compelling opportunity to build on the recent buyout of Novartis’ stake in GSK Consumer Healthcare, to create a new world-leading consumer healthcare business and to deliver further significant shareholder value. The proposed transaction also supports GSK’s key priority of strengthening its pharmaceuticals business over the next few years by increasing cashflows and providing an effective pathway through the separation of GSK Consumer Healthcare to build further support for investment in its R&D pipeline.

New Consumer Healthcare Joint Venture

The new Joint Venture will be well-positioned to deliver stronger sales, cash flow and earnings growth driven by category leading Power Brands, science-based innovation and substantial cost synergies. The combination will bring together two highly complementary portfolios of trusted consumer health brands, including GSK’s Sensodyne, Voltaren and Panadol and Pfizer’s Advil, Centrum and Caltrate. The Joint Venture will be a category leader in Pain Relief, Respiratory, Vitamin and Mineral Supplements, Digestive Health, Skin Health and Therapeutic Oral Health. The Joint Venture will be the global leader in OTC products with a market share of 7.3% ahead of its nearest competitor at 4.1% and have number 1 or 2 market share positions in all key geographies, including the US and China.

The proposed transaction is expected to realise substantial cost synergies, with the Joint Venture expected to generate total annual cost savings of £0.5 billion by 2022 for expected total cash costs of £0.9 billion and non-cash charges of £0.3 billion. Planned divestments targeting around £1 billion of net proceeds are expected to cover the cash costs of the integration. Up to 25% of the cost savings are intended to be reinvested in the business to support innovation and other growth opportunities. Overall the Joint Venture will target an Adjusted operating margin percentage in the ‘mid-to-high 20’s’ by 2022.

When GSK brought out Novartis for Consumer health care in July 2018 it agreed i a price of $13 billion, the transaction completed
In December 2018 GSK agreed to sell of Horlicks for $3.9 billion and completed it. GSK retained 5% holding in GSK HUL india.
GSK also sold Unilver the rights of brands related to Horlicks for £390 million, none of the above transactions effected any part of GSL Consumer health with Pfizer being the minor partner holding 32%

Another feather in Emma's bonnet , to actually sell off Horlicks and retain 5% of
GSK India is not part of the GSK Consumer Healthcare Joint Venture with Pfizer and the merger of GSK India and HUL therefore does not impact the Joint Venture.

No deramping, just offering a view on how to capitalize and not lose out. 50% of a gain is better than 100% of a loss.

Remember when the RI started trading in Germany since last week

Is it a case of Goldman just buying the RI on the DAX at the lowest price when they started trading and will they offload before the last date of trading the RI next week.

With the EU considering using a Vaccine passport , the careful use of the word "Considering" this may cause UK passport holders some issues.

Bieng out of the EU could pose a problem as the data bases used in the EU wil show people who are vaccinated. Will the UK have a similar system and be able to issue a vaccine document to show persons traveling have had the vaccine?

TUI will be at an advantage due to there European bases and countries they operate from, where the likes of Jet2 do not have EU based operations.

The RI issue, how many have considered selling 50% of the RI, and holding the other 50% in thier main holding as ordinary shares, it could pay to cover both scenarios, by selling part of the RI.
Just thoughts, nothing more

No soupdragon.
I was a member a number of years back and have a good understanding of the Canadian Exchange , Sedi and Sedar, which help a lot, as you do not get MD&A in the UK market.

the reverse takeover is eyeopening on the TMX .

Have held shares in NFX when it was Levrett Plc and Boehringer Ingelheim were investors and were working on a JV , but they went to NFX with changes and its been down hill since with the odd glimmer of hope

I like the technology still and stay invested , its a small investment

papucel
OXB as not changed in 3 years, even in May 218 when they did the share consolidation and the SP went to £10.50, it sstill never reached that figure again
the consolidation I recall was done to entice Investment fund managers to buy the stock, as most don't bother with serious pharma investment where the share is priced under £5.00 .Some have tight rules in place, so OXB did the consolidation, maybe OXB will get some positive news on Opthalmolgy Treatments soon

They have to adhere to the original deal and the patents are NFX , I would not trust DT as far as I could throw him, but it is what it is now.

Cautionary note, be prepared to see NFX swallowed up , as DT and DG know they left the balance sheet bare and have a massive say on Elbers snatching the assets.

Soupdragon, its like a lot of UK companys that listed and did reverse take overs on the TMX and then went private once the assets were snatched.

I am not saying this is the case, but needs careful watching Pascal Hughes is from Leveritt before NFX reverse takeover.

NFX board should take a long hard look at Medicago to see how you progress a company and have the right backers who became owners. Have a look at Medicago and its history with Phillip Morris how it went from the TMX when Mitsubishi bieng a large shareholder with Phillip Morris.

Best of luck all

While it as traded as a company on the TMX, its filing share still required and trades as Financial company.

I note David Tapolczay and Pascal Hughes on board,

The same Taploczay that sold his shareholding and crashed the SP,,, Will Dan G come out of the rabbit hole as well.

I am just posing questions soupodragon, as NFX is not well run is it??

Soupdragon

Where is the capital coming from, as Kelly ventures have not got 2 bob and a rabbit .
If you study the MD&A plus the Financial statements and Auditors report they are horrendous reading .

Serious question, one can see why NFX say nothing, dose this looks like asset stripping ?

14/01/21
NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for adult women with advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, who have completed and shown a response to platinum-based chemotherapy.

The drug will now be made immediately available through the Cancer Drugs Fund for women regardless of whether or not they have a BRCA gene mutation, meaning up to 3,000 people could potentially benefit from the medicine.

Niraparib, a once-daily oral medicine given when advanced ovarian cancer is in remission in order to delay its return, is a PARP inhibitor that works by preventing ovarian cancer cells from being able to repair damage to their DNA. The aim of treatment is to put off the need for further chemotherapy for as long possible, allowing women to live the best quality of life they can.

The treatment has been shown to significantly extend the time it took for a woman’s cancer to return, and in some participants in its pivotal Phase III trial, this was by over a year compared with placebo.

Ovarian cancer remains a significant health challenge in the UK, where incidence rates are among the highest in Europe, and survival rates are among the lowest. Of the approximately 7,500 women that are diagnosed with ovarian cancer in the UK each year, nearly 60% will be diagnosed at a late stage, where their cancer has spread and is potentially incurable.

Jonathan Ledermann, Professor of Medical Oncology at the UCL Cancer Institute and Director of the Cancer Research UK and UCL Cancer Trials Centre, said: “Today’s decision marks a turning point in advanced ovarian cancer treatment, allowing clinicians to use a key therapy at an earlier phase of treatment and in many more women than ever before.

“This could significantly increase the likelihood that we can delay a woman’s cancer from progressing – for months, perhaps even years longer than is currently possible. Maintenance therapy has already changed how we treat ovarian cancer and the decision to recommend niraparib is

Mr Blackie, you can sell your rights now without buying them, you dont have to pay for them.
Apologies I saw you posted twice.. Best of luck to all

Mr Blackie
Yes the 1.07 =0.95p.

You just select sell on the RI shares in your portfolio platform , which should be seperate from the Ordinary shares and you will get a price for the RI, it will vary, but be around £2.55 to £2.68 .

You may not get the total price difference, but IMO, the SP is trading above value at present.

TUI are doubling the shares in Issue, so I would expect the SP to be volatile next week leading up to the ceasing of RI shares being able to be sold

Look back and see what GSK paid Novartis its stake in the Joint consumer health care they held.

Key extract investors should focus on from 2018.
Barclays analysts said Glaxo was paying less than 17 times expected 2018 core earnings for the joint venture stake, while sources have told Reuters that both Merck and Pfizer had asked for up to 20 times for their respective assets.

FRANKFURT/ZURICH (Reuters) - GlaxoSmithKline GSK.L is buying Novartis NOVN.S out of their consumer healthcare joint venture for $13 billion (9 billion pounds), taking full control of products including Sensodyne toothpaste, Panadol headache tablets, muscle gel Voltaren, and Nicotinell patches.

GSK's biggest move since Emma Walmsley became chief executive last year follows the British drugmaker's decision last week to quit the race to buy Pfizer's PFE.N consumer healthcare business, endangering an auction the U.S. company hoped would bring in as much as $20 billion.

Consumer remedies sold over the counter have lower margins than prescription drugs, but they are typically well-known brands with customers.

“The proposed transaction addresses one of our key capital allocation priorities and will allow GSK shareholders to capture the full value of one of the world’s leading consumer healthcare businesses,” Walmsley said in a statement on Tuesday.

Although some pharmaceuticals groups have been keen to hold consumer care products, intense price competition online, mainly from Amazon AMZN.O, as well as cheaper store-brand products, have led others to doubt their stable returns longer-term.
The British group's shares jumped 6.1 percent, outperforming a 2 percent gain in the STOXX Europe 600 Health Care .SXDP.

GSK said that as well as ending the Novartis venture it would start a strategic review of Horlicks and other consumer nutrition products, sparking another potential industry shake-up. The review will include an assessment of its majority stake in India-listed GlaxoSmithKline Consumer Healthcare GLSM.NS.

“The decision not to pay up for Pfizer’s consumer assets will have led GSK CEO Emma Walmsley to remove uncertainty by bringing all the consumer revenues in-house and assisting toward efficient capital allocation,” said Ketan Patel, co-manager of the Amity UK Fund at EdenTree Investment Management, who holds GSK shares.

“Long-term investors will welcome the greater clarity this brings to both companies.”
GSK said that the purchase would boost adjusted earnings and cash flows.

Pfizer has been struggling to sell its consumer healthcare business after GSK and Reckitt Benckiser RB.L both dropped out of the bidding, while differences in price expectations have also hobbled German drugmaker Merck KGaA's MRCG.DE attempts to sell its consumer products unit.

You have to exercise your Rights Issue, if you don't you lose them. It's all clear in documentation issued by TUI and regulated.

Why would any person wait and lose them, the Rights Issue, is not the same as IAG or RR.

It cost investors nothing to sell their rights issue at this time, only a dealing charge.If you dont exercise them and pay for them, you should sell them .